The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
Dong Il Park, Sun Young Kim, Ju Ock Kim, Sung Soo Jung, Hee Sun Park, Jae Young Moon, Chae Uk Chung, Song Soo Kim, Jae Hee Seo, Jeong Eun Lee
Tuberc Respir Dis. 2015;78(4):315-320.   Published online 2015 Oct 1     DOI: https://doi.org/10.4046/trd.2015.78.4.315
Citations to this article as recorded by Crossref logo
Reasonable Timing of Radiotherapy for Stage IV Non-Small-Cell Lung Cancer During Targeted Therapy Based on Tumour Volume Change
Qingsong Li, Na Liang, Xia Zhang, Yi Zhang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yinxiang Hu, Yichao Geng, Xiaxia Chen, Bing Lu
Frontiers in Oncology.2021;[Epub]     CrossRef
Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth
Kaitlyn Johnson, Axel Gomez, Jackson Burton, Douglas White, Arijit Chakravarty, Annette Schmid, Dean Bottino
European Journal of Cancer.2019; 109: 196.     CrossRef
Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors
Shanshan Yu, Xingchen Wang, Xiaoyan Wang, Xueyuan Wu, Rongrong Xu, Xiaoqi Wang, Xue Zhang, Chunhong Zhang, Kun Chen, Dezhi Cheng, Li Wenfeng
Journal of Cancer Research and Therapeutics.2019; 15(7): 1574.     CrossRef